Printer Friendly

POSSIS MEDICAL BEGINS U.S. HUMAN CLINICAL STUDY OF ITS PERMA-SEAL DIALYSIS ACCESS GRAFT

 MINNEAPOLIS, July 15 /PRNewswire/ -- Possis Corporation (NASDAQ-NMS: POSS) announced today that Possis Medical, Inc. (PMI), its wholly owned subsidiary, has begun U.S. human clinical implants of it Perma-Seal(R) Dialysis Access Graft. These implants are being conducted under an investigational device exemption (IDE) approved by the U.S. Food and Drug Administration. Meaningful results and conclusions concerning the long-term efficacy of the graft requires cumulative data from implant patients measured over time. The status of the clinical study will be announced at appropriate times.
 Perma-Seal is a synthetic dialysis graft uniquely constructed of silicone elastomeric fibers and polyester yarn. The proprietary design of the graft provides self-sealing characteristics to help stop bleeding following removal of dialysis needles and to help minimize deposits or stenoses which can lead to graft failure. Perma-Seal's unique combination of strength and elasticity also provides for durability, kink resistance, ease of needle cannulation and ease of handling. PMI believes Perma-Seal offers important advantages for the estimated 40,000 patients per year worldwide who require graft implantation for kidney dialysis.
 PMI's Perma-Flow(R) Coronary Graft, currently undergoing U.S. human clinical study, has been implanted in four patients. Results from clinical follow-up testing continue to be favorable. Taken together, the Perma-Seal and Perma-Flow Grafts further establish PMI as an emerging provider of synthetic peripheral grafts and a pioneer in providing synthetic coronary grafts.
 -0- 7/15/93
 /CONTACT: Robert G. Dutcher of Possis Medical, 612-550-1010/
 (POSS)


CO: Possis Corporation; Possis Medical, Inc. ST: Minnesota IN: MTC SU:

DB -- MN023 -- 2053 07/15/93 14:09 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 15, 1993
Words:260
Previous Article:CRYSTAL BOTTLED WATER PARENT COMPANYSENDING WATER TO MIDWEST FLOOD VICTIMS
Next Article:RAYTHEON'S 2ND QUARTER EARNINGS INCREASE BY 8.3 PERCENT
Topics:


Related Articles
POSSIS MEDICAL RECEIVES FDA APPROVAL FOR IDE APPLICATION
POSSIS MEDICAL, INC. ANNOUNCES SALE OF PACEMAKER LEADS BUSINESS
POSSIS MEDICAL ENTERS INTO A SUPPLY AND DISTRIBUTION AGREEMENT WITH BARD VASCULAR SYSTEMS
POSSIS MEDICAL, INC., APPOINTS PROMINENT PHYSICIANS TO MEDICAL ADVISORY COMMITTEE
POSSIS MEDICAL ENTERS INTO A SUPPLY AND DISTRIBUTION AGREEMENT WITH BARD VASCULAR SYSTEMS
POSSIS MEDICAL, INC. APPLIES TO FDA FOR COMMENCEMENT OF ANGIOJET(TM) CORONARY THROMBECTOMY STUDY
POSSIS MEDICAL, INC. TO BEGIN ANGIOJET(TM) CORONARY THROMBECTOMY STUDY
POSSIS MEDICAL, INC. REPORTS THIRD QUARTER RESULTS
Possis Medical, Inc. Submits Perma-Seal Graft Clinical Data Summary to the FDA
Possis Medical, Inc. Reports Third Quarter Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters